Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Thoracic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Thoracic Neoplasm

Cancer Family

Thoracic Neoplasm

CI-CAN-00000054Explore in graph →

Non-malignant2,891 active trials51 approved drugs626 evidence items

NCIt: C3406
MeSH: D013899

Overview
Statistics
Survival
Genomics51
Variants & evidence626
Drugs128
Trials12160
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (479)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 376–400 of 479 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.
· Proc Natl Acad Sci U S A · 2016 · PMID 26917690 · validated civic_curation pubmed
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.
· JAMA Oncol · 2015 · PMID 26181354 · validated civic_curation pubmed
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
· Clin Lung Cancer · 2015 · PMID 25769807 · validated civic_curation pubmed
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
· Clin Cancer Res · 2009 · PMID 19147750 · validated civic_curation pubmed
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.
· Proc Natl Acad Sci U S A · 2008 · PMID 18227510 · validated civic_curation pubmed
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
· Sci Transl Med · 2010 · PMID 21160078 · validated civic_curation pubmed
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
· Nature · 2007 · PMID 17625570 · validated civic_curation

Showing 376–400 of 479 publications

← Previous
1
…
15
16
17
…
20
Next →

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.

· EMBO Mol Med · 2016 · PMID 26758680 · validated civic_curation pubmed

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

· Cancer Cell · 2006 · PMID 16730237 · validated civic_curation pubmed

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

· Science · 2004 · PMID 15118125 · validated civic_curation pubmed

The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

· Cell · 2012 · PMID 22541434 · validated civic_curation pubmed

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

· Nat Med · 2008 · PMID 19029981 · validated civic_curation pubmed

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

· Clin Cancer Res · 2014 · PMID 24771645 · validated civic_curation pubmed

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.

· PLoS One · 2011 · PMID 21666749 · validated civic_curation pubmed

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

· Science · 2007 · PMID 17463250 · validated civic_curation pubmed

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

· Cancer Discov · 2012 · PMID 22961667 · validated civic_curation pubmed

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.

· Br J Cancer · 2012 · PMID 22333600 · validated civic_curation pubmed

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

· Cell Rep · 2014 · PMID 25199829 · validated civic_curation pubmed

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

· Cell Rep · 2014 · PMID 24685132 · validated civic_curation pubmed

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.

· Proc Natl Acad Sci U S A · 2009 · PMID 19122144 · validated civic_curation pubmed

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.

· Mol Cancer · 2014 · PMID 24898067 · validated civic_curation pubmed

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

· Cancer Res · 2008 · PMID 18593892 · validated civic_curation pubmed

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

· Oncogene · 2011 · PMID 21258415 · validated civic_curation pubmed

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

· Cancer Discov · 2016 · PMID 26554404 · validated civic_curation pubmed

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

· Cancer Discov · 2014 · PMID 24675041 · validated civic_curation pubmed